Compare Davita Inc (DVA) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs PulteGroup, Inc. — how do they compare? Davita Inc trades at $230.69 (market cap $14.92B), while PulteGroup, Inc. trades at $126.08 (market cap $23.73B). The key difference: PulteGroup, Inc. is the larger of the two by market cap, and PulteGroup, Inc. pays a 0.83% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | PHM | |
|---|---|---|
Market Cap | $14.92B | $23.73B |
Sector | Health | Consumer Cyclical |
52-Week High | $235.71 | $142.56 |
52-Week Low | $103.87 | $108.00 |
Enterprise Value | $27.47B | $23.69B |
Dividend Yield | — | 0.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
PulteGroup (PHM) trades at $123.75, down 0.8% on the day, with a bullish technical signal but mixed recent earnings. The stock shows strong profitability with a 12.14% net margin and attractive valuation at a P/E of 11.97. Recent news highlights new community developments and market sensitivity to mortgage rates. Cash flow trends improved in 2025 with net cash flow of $355 million.
Outlook remains cautiously optimistic with a consensus price target of $146, implying 18% upside. Risks include housing affordability pressures and recent earnings misses. Analyst sentiment is balanced with 45% buy ratings. The stock's valuation and dividend support a constructive view amid sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
